Navigation Links
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Date:10/15/2008

ed patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Disorders Drug Pipeline Insight 2014" report to their offering. ... in US is one of the largest segments of pharmaceuticals ... alarming rate, while the available therapies were unable to meet ... in the market for CNS disorder, especially over the past ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... HAMILTON, N.J., Sept. 14 MedAvante, Inc., the leader ... that the U.S. Food and Drug Administration (FDA) has ... psychiatric medication including primary outcome data collected by MedAvante ... a Johnson & Johnson company, submitted the NDA for ...
... privately-held biotechnology company focused on developing a novel class ... Quinton Oswald has joined the company as Chief Executive ... experience and management expertise to the CEO role. Most ... President & Business Unit Head for the Tissue Growth ...
Cached Medicine Technology:FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 2FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 3Quinton Oswald Named Chief Executive Officer of SARcode Corporation 2Quinton Oswald Named Chief Executive Officer of SARcode Corporation 3
(Date:8/30/2014)... 2014 Patients suffering from vitiligo can ... a new review published by Daily Gossip. , ... so there is no wonder that numerous sufferers search ... Vitiligo Treatment is one of the most appreciated such ... promises to stop the spread of this disorder immediately, ...
(Date:8/30/2014)... 30, 2014 The Plastic Surgery Group ... Jersey and even in the U.S. to provide clients ... off of patients’ waists with deep-tissue heating. , Unlike ... sections, Vanquish is more inclusive to target large sections ... comfortably under panels about one inch away from their ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Richmond, VA (PRWEB) August 30, 2014 Seniors ... several articles recently that focus on Alzheimer’s Disease, Dementia, ... recently revealed to the public of being diagnosed with the ... his latest movie, “I’ll Be Me”. The movie, out ... life while focusing on his diagnosis of the disease – ...
(Date:8/30/2014)... Randy Dotinga HealthDay ... About one in five patients operated on for broken bones ... surgery, a new study finds. Less-educated patients and ... more likely to be "doctor shoppers," said study lead author ... Ky. Overall, he said, the study suggests that doctors aren,t ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... 6 Prescription pediatric drugs represent,an enormous market, with ... growth is forecast at a modest 3.2%, reaching $43,billion ... share of 11.7%, is,expected to achieve the highest growth ... Kalorama Information,s new report The World Market for,Pediatric Drugs., ...
... Medical Solutions, Inc.,(Rising), a leading medical cost ... Index (PCI) "Top Growth Company" list for ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ), (Logo: http://www.newscom.com/cgi-bin/prnh/20080206/AQW030-a ... Inc. ( http://www.entrex.net ), is a,proprietary benchmarking ...
... restatement of Beth Israel Deaconess,Medical Center audit, ... apply the same Sarbanes-Oxley standards used by Massbank ... the board of Beth Israel,Deaconess Medical Center (BIDMC), ... East. Bufferd is also the retired treasurer of,Massachusetts ...
... The Female Health Company,(Amex: FHC ) ... conference call,to discuss its operating results for the ... (EST) on Wednesday, February 13, 2008. The Company ... earlier the same day., Shareholders and other ...
... Medical cost increases for,employers throughout the world ... according to a poll of insurance companies conducted ... The poll also found,that, in a vast majority ... rate of inflation., Nearly three-fourths (71 percent) ...
... A new statewide survey,released today shows that ... tax revenue for programs to prevent kids,from starting ... poll of 500 Virginia voters was released today ... Lung Association and,the Campaign for Tobacco-Free Kids. The ...
Cached Medicine News:Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Rising Medical Solutions, Inc. Ranks Fifth on the Private Company Index (PCI) 'Top Growth Companies' List 2Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 2Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 3Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 2Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 3
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Medicine Products: